Pathophysiological cytokine network in primary Sjögren's syndrome

Presse Medicale

Volumn 41, Issue 9 PART2, 2012, Pages

  Pers, Jacques Olivier ^a   Lahiri, Ayan ^a   Tobón, Gabriel J ^a   Youinou, Pierre ^a  

^a UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BETA INTERFERON; FLT3 LIGAND; HLA ANTIGEN CLASS 2; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; APOPTOSIS; B LYMPHOCYTE; CELL INTERACTION; CELL POLARITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LEUKEMOGENESIS; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; NONHUMAN; PRIMARY SJOEGREN SYNDROME; REGULATORY T LYMPHOCYTE; SALIVARY GLAND; SHORT SURVEY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84866001266     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.04.029     Document Type: Short Survey

References (81)

1. Moutsopoulos H.M. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994, 72:162-165.
2. Xanthou G., Tapinos N.I., Polihronis M., Nezis I.P., Margaritis L.H., Moutsopoulos H.M. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome. Clin Exp Immunol 1999, 118:154-163.
3. Bodeutsch C., de Wilde P.C., Kater L., van den Hoogen F.H., Hene R.J., van Houwelingen J.C., et al. Monotypic plasma cells in labial salivary glands of patients with Sjögren's syndrome: prognosticator for systemic lymphoproliferative disease. J Clin Pathol 1993, 46:123-128.
4. Tapinos N.I., Polihronis M., Tzioufas A.G., Skopouli F.N. Immunopathology of Sjögren's syndrome. Ann Med Interne (Paris) 1998, 149:17-24.
5. Stott D.I., Hiepe F., Hummel M., Steinhauser G., Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest 1998, 102:938-946.
6. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010, 34:400-407.
7. Youinou P., Pers J.O. Disturbance of cytokine networks in Sjögren's syndrome. Arthritis Res Ther 2011, 13:227.
8. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005, 52:1534-1544.
9. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006, 103:2770-2775.
10. Emamian E.S., Leon J.M., Lessard C.J., Grandits M., Baechler E.C., Gaffney P.M., et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009, 10:285-296.
11. Ittah M., Miceli-Richard C., Eric Gottenberg J., Lavie F., Lazure T., Ba N., et al. B-cell activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006, 8:R51.
12. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type-I interferon. Nat Med 1999, 5:919-923.
13. Mavragani C.P., Crow M.K. Activation of the type-I interferon pathway in primary Sjögren's syndrome. J Autoimmun 2010, 35:225-231.
14. Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002, 127:386-392.
15. Abu-Helu R.F., Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. Induction of salivary gland epithelial cell injury in Sjögren's syndrome: in vitro assessment of T-cell derived cytokines and Fas protein expression. J Autoimmun 2001, 17:141-153.
16. Fox R.I., Kang H.I., Ando D., Abrams J., Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994, 152:5532-5539.
17. Ohyama Y., Nakamura S., Matsuzaki G., Shinohara M., Hiroki A., Fujimura T., et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996, 39:1376-1384.
18. Mitsias D.I., Tzioufas A.G., Veiopoulou C., Zintzaras E., Tassios I.K., Kogopoulou O., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol 2002, 128:562-568.
19. Amft N., Bowman S.J. Chemokines and cell trafficking in Sjögren's syndrome. Scand J Immunol 2001, 54:62-69.
20. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8.
21. Hagiwara E., Pando J., Ishigatsubo Y., Klinman D.M. Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjögren's syndrome. J Rheumatol 1998, 25:89-93.
22. van Woerkom J.M., Kruize A.A., Wenting-van Wijk M.J., Knol E., Bihari I.C., Jacobs J.W., et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome. Ann Rheum Dis 2005, 64:1474-1479.
23. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008, 58:734-743.
24. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
25. Sakai A., Sugawara Y., Kuroishi T., Sasano T., Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008, 181:2898-2906.
26. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos N.M., Moutsopoulos H.M. Foxp3+ T-regulatory cells in Sjögren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008, 173:1389-1396.
27. Bikker A.K.A., Wenting M., Versnel M.A., Bijlsma J.W., Lafeber F.P., van Roon J.A. Increased interleukin (IL)-7R alpha expression in salivary glands of patients with primary Sjögren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity. Ann Rheum Dis 2012, 1(6):1027-1033.
28. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
29. Daridon C., Guerrier T., Devauchelle V., Saraux A., Pers J.O., Youinou P. Polarization of B effector cells in Sjögren's syndrome. Autoimmun Rev 2007, 6:427-431.
30. Le Pottier L., Devauchelle V., Fautrel A., Daridon C., Saraux A., Youinou P., et al. Ectopic germinal centers are rare in Sjögren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009, 182:3540-3547.
31. Binard A., Le Pottier L., Devauchelle-Pensec V., Saraux A., Youinou P., Pers J.O. Is the blood B-cell subset profile diagnostic for Sjögren's syndrome. Ann Rheum Dis 2009, 68:1447-1452.
32. Youinou P., Taher T.E., Pers J.O., Mageed R.A., Renaudineau Y. B-lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum 2009, 60:1873-1880.
33. Szodoray P., Alex P., Brun J.G., Centola M., Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004, 59:592-599.
34. Shen L., Suresh L., Li H., Zhang C., Kumar V., Pankewycz O., et al. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans. Clin Immunol 2009, 130:304-312.
35. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175.
36. Hillion S., Dueymes M., Youinou P., Jamin C. IL-6 contributes to the expression of RAGs in human mature B cells. J Immunol 2007, 179:6790-6798.
37. Lisovsky M., Braun S.E., Ge Y., Takahira H., Lu L., Savchenko V.G., et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996, 10:1012-1018.
38. Antonysamy M.A., Thomson A.W. Flt3-ligand (FL) and its influence on immune reactivity. Cytokine 2000, 12:87-100.
39. Bertrand F.E., Eckfeldt C.E., Fink J.R., Lysholm A.S., Pribyl J.A., Shah N., et al. Microenvironmental influences on human B-cell development. Immunol Rev 2000, 175:175-186.
40. Drexler H.G., Quentmeier H. FLT3: receptor and ligand. Growth Factors 2004, 22:71-73.
41. McKenna H.J., Stocking K.L., Miller R.E., Brasel K., De Smedt T., Maraskovsky E., et al. Mice lacking FLT3-ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000, 95:3489-3497.
42. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
43. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
44. Tobon G.J., Renaudineau Y., Hillion S., Cornec D., Devauchelle-Pensec V., Youinou P., et al. The Fms-like tyrosine kinase 3-ligand, a mediator of B-cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2010, 62:3447-3456.
45. Mackay F., Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
46. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J Exp Med 1999, 189:1747-1756.
47. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., et al. BLyS: member of the tumor necrosis factor family and B-lymphocyte stimulator. Science 1999, 285:260-263.
48. Hahne M., Kataoka T., Schroter M., Hofmann K., Irmler M., Bodmer J.L., et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998, 188:1185-1190.
49. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
50. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
51. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
52. Dorner T., Putterman C. B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus. Arthritis Res 2001, 3:197-199.
53. Batten M., Fletcher C., Ng L.G., Groom J., Wheway J., Laabi Y., et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B-cell lymphoma. J Immunol 2004, 172:812-822.
54. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., et al. BAFF and MyD88 signals promote a lupus like disease independent of T cells. J Exp Med 2007, 204:1959-1971.
55. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., et al. TACI-Ig neutralizes molecules critical for B-cell development and autoimmune disease. Impaired B-cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
56. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
57. Rahman Z.S., Rao S.P., Kalled S.L., Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003, 198:1157-1169.
58. Daridon C., Youinou P., Pers J.O. BAFF, APRIL, TWE-PRIL: who's who?. Autoimmun Rev 2008, 7:267-271.
59. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003, 62:168-171.
60. Collins C.E., Gavin A.L., Migone T.S., Hilbert D.M., Nemazee D., Stohl W. B-lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8:R6.
61. Carter R.H., Zhao H., Liu X., Pelletier M., Chatham W., Kimberly R., et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005, 52:3943-3954.
62. Gao H., Bian A., Zheng Y., Li R., Ji Q., Huang G., et al. sBAFF mutants induce neutralizing antibodies against BAFF. FEBS Lett 2007, 581:581-586.
63. Le Pottier L., Bendaoud B., Dueymes M., Daridon C., Youinou P., Shoenfeld Y., et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007, 27:257-265.
64. Le Pottier L., Bendaoud B., Renaudineau Y., Youinou P., Pers J.O., Daridon C. New Elisa for B-cell activating factor. Clin Chem 2009, 55:1843-1851.
65. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
66. d'Arbonneau F., Pers J.O., Devauchelle V., Pennec Y., Saraux A., Youinou P. BAFF-induced changes in B-cell antigen receptor-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006, 54:115-126.
67. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B-lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007, 56:1134-1144.
68. Daridon C., Pers J.O., Devauchelle V., Martins-Carvalho C., Hutin P., Pennec Y.L., et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006, 54:2280-2288.
69. Loder F., Mutschler B., Ray R.J., Paige C.J., Sideras P., Torres R., et al. B-cell development in the spleen takes place in discrete steps and is determined by the quality of B-cell receptor-derived signals. J Exp Med 1999, 190:75-89.
70. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
71. Szodoray P., Alex P., Jonsson M.V., Knowlton N., Dozmorov I., Nakken B., et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005, 117:168-176.
72. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B-lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
73. Nossent J.C., Lester S., Zahra D., Mackay C.R., Rischmueller M. Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjögren's syndrome. Rheumatology (Oxford) 2008, 47:1311-1316.
74. Durali D., de Goer de Herve M.G., Giron-Michel J., Azzarone B., Delfraissy J.F., Taoufik Y In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood 2003, 102:4084-4089.
75. Alimzhanov M.B., Kuprash D.V., Kosco-Vilbois M.H., Luz A., Turetskaya R.L., Tarakhovsky A., et al. Abnormal development of secondary lymphoid tissues in lymphotoxin-beta-deficient mice. Proc Natl Acad Sci U S A 1997, 94:9302-9307.
76. Kratz A., Campos-Neto A., Hanson M.S., Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996, 183:1461-1472.
77. Gatumu M.K., Skarstein K., Papandile A., Browning J.L., Fava R.A., Bolstad A.I. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 2009, 11:R24.
78. Solomon A., Dursun D., Liu Z., Xie Y., Macri A., Pflugfelder S.C. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001, 42:2283-2292.
79. Chen Y.T., Nikulina K., Lazarev S., Bahrami A.F., Noble L.B., Gallup M., et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren's syndrome. Am J Pathol 2010, 177:1333-1343.
80. Ogawa N., Ping L., Zhenjun L., Takada Y., Sugai S. Involvement of the interferon-gamma-induced T-cell attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine-induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum 2002, 46:2730-2741.
81. Moriyama M., Hayashida J., Toyoshima T., Ohyama Y., Shinozaki S., Tanaka A., et al. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren's syndrome. Clin Exp Immunol 2012.